SATB2 and colorectal carcinoma: SATB2 was also prognostic for DSS (SATB2-high 105.8 months vs. SATB2-low/absent 90.6 months, p = 0.023), but not for OS (SATB2-high 92.3 months vs. SATB2-low/absent 78.8 months, p = 0.072) or DFS (SATB2-high 101 months vs. SATB2-low/absent 89 months, p = 0.163) in MSI-H CRC.